Moleculin Biotech (NASDAQ:MBRX) Releases Quarterly Earnings Results

Moleculin Biotech (NASDAQ:MBRX) released its quarterly earnings results on Thursday. The company reported ($1.40) EPS for the quarter, beating the consensus estimate of ($1.55) by $0.15, FiscalAI reports.

Moleculin Biotech Trading Up 9.4%

Shares of Moleculin Biotech stock traded up $0.05 during mid-day trading on Thursday, hitting $0.57. 1,322,819 shares of the stock were exchanged, compared to its average volume of 567,823. The stock has a market capitalization of $4.06 million, a price-to-earnings ratio of -0.03 and a beta of 1.83. Moleculin Biotech has a twelve month low of $0.16 and a twelve month high of $17.23. The company has a 50-day simple moving average of $2.10 and a 200 day simple moving average of $2.54.

Hedge Funds Weigh In On Moleculin Biotech

A hedge fund recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC bought a new position in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned about 1.11% of Moleculin Biotech as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 15.52% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Wall Street Zen downgraded Moleculin Biotech from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a report on Friday, July 17th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Moleculin Biotech presently has an average rating of “Hold” and a consensus price target of $22.00.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.